Facioscapulohumeral Muscular Dystrophy Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Dyne Therapeutics, GSK, Roche, Facio Therapies, Fulcrum Therapeutics, My

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Facioscapulohumeral Muscular Dystrophy pipeline constitutes 10+ key companies continuously working towards developing 10+ Facioscapulohumeral Muscular Dystrophy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Facioscapulohumeral Muscular Dystrophy Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Facioscapulohumeral Muscular Dystrophy Market.

The Facioscapulohumeral Muscular Dystrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Facioscapulohumeral Muscular Dystrophy Pipeline Report: https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Facioscapulohumeral Muscular Dystrophy treatment therapies with a considerable amount of success over the years.
• Facioscapulohumeral Muscular Dystrophy companies working in the treatment market are Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics, and others, are developing therapies for the Facioscapulohumeral Muscular Dystrophy treatment
• Emerging Facioscapulohumeral Muscular Dystrophy therapies in the different phases of clinical trials are- DYNE-301, MC-DX4, AOC 1020, ATYR 1940, Losmapimod, and others are expected to have a significant impact on the Facioscapulohumeral Muscular Dystrophy market in the coming years.
• In June 2022, Fulcrum Therapeutics has commenced a multi-national trial employing a randomized, double-blind, placebo-controlled methodology to assess the effectiveness and safety of losmapimod for treating FSHD. In this trial, patients will be randomly allocated in a 1:1 ratio to receive either losmapimod orally, through a 15 mg tablet taken twice a day, or a placebo. The evaluation will span a 48-week treatment duration, with the primary focus on determining the absolute change from the initial state in Reachable Workspace (RWS). Secondary endpoints will involve assessing factors like muscle fat infiltration (MFI), Patient Global Impression of Change (PGIC), and Quality of Life in Neurological Disorders of the upper extremity (Neuro QoL UE). Additionally, the REACH trial will encompass patient-centered evaluations concerning healthcare utilization.

Facioscapulohumeral Muscular Dystrophy Overview
Facioscapulohumeral muscular dystrophy (FSHD) is a genetic muscular disorder primarily impacting muscles in areas such as the face, shoulder blades, and upper arms, displaying significant effects in these regions.

Get a Free Sample PDF Report to know more about Facioscapulohumeral Muscular Dystrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Facioscapulohumeral Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include:
• DYNE-301: Dyne Therapeutics
• MC-DX4: miRecule
• AOC 1020: Avidity Biosciences
• ATYR 1940: aTyr Pharma
• Losmapimod: Fulcrum Therapeutics

Facioscapulohumeral Muscular Dystrophy Route of Administration
Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Facioscapulohumeral Muscular Dystrophy Molecule Type
Facioscapulohumeral Muscular Dystrophy Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Facioscapulohumeral Muscular Dystrophy Pipeline Therapeutics Assessment
• Facioscapulohumeral Muscular Dystrophy Assessment by Product Type
• Facioscapulohumeral Muscular Dystrophy By Stage and Product Type
• Facioscapulohumeral Muscular Dystrophy Assessment by Route of Administration
• Facioscapulohumeral Muscular Dystrophy By Stage and Route of Administration
• Facioscapulohumeral Muscular Dystrophy Assessment by Molecule Type
• Facioscapulohumeral Muscular Dystrophy by Stage and Molecule Type

DelveInsight's Facioscapulohumeral Muscular Dystrophy Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Facioscapulohumeral Muscular Dystrophy product details are provided in the report. Download the Facioscapulohumeral Muscular Dystrophy pipeline report to learn more about the emerging Facioscapulohumeral Muscular Dystrophy therapies at:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Facioscapulohumeral Muscular Dystrophy Therapeutics Market include:
Key companies developing therapies for Facioscapulohumeral Muscular Dystrophy are - Dyne Therapeutics, GSK, Roche, Facio Therapies, Fulcrum Therapeutics, Myocea, Avidity Biosciences, and others.

Facioscapulohumeral Muscular Dystrophy Pipeline Analysis:
The Facioscapulohumeral Muscular Dystrophy pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Facioscapulohumeral Muscular Dystrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Facioscapulohumeral Muscular Dystrophy Treatment.
• Facioscapulohumeral Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Facioscapulohumeral Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Facioscapulohumeral Muscular Dystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Facioscapulohumeral Muscular Dystrophy drugs and therapies-
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Facioscapulohumeral Muscular Dystrophy Pipeline Market Drivers
• Advancement in medical technology, investigation into the molecular consequences of DUX4 expression, demand for effective treatment options and novel therapies are some of the important factors that are fueling the Facioscapulohumeral Muscular Dystrophy Market.

Facioscapulohumeral Muscular Dystrophy Pipeline Market Barriers
• However, lack of approved therapies, complications involved with facioscapulohumeral muscular dystrophy and other factors are creating obstacles in the Facioscapulohumeral Muscular Dystrophy Market growth.

Scope of Facioscapulohumeral Muscular Dystrophy Pipeline Drug Insight
• Coverage: Global
• Key Facioscapulohumeral Muscular Dystrophy Companies: Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics, and others
• Key Facioscapulohumeral Muscular Dystrophy Therapies: DYNE-301, MC-DX4, AOC 1020, ATYR 1940, Losmapimod, and others
• Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment: Facioscapulohumeral Muscular Dystrophy current marketed and Facioscapulohumeral Muscular Dystrophy emerging therapies
• Facioscapulohumeral Muscular Dystrophy Market Dynamics: Facioscapulohumeral Muscular Dystrophy market drivers and Facioscapulohumeral Muscular Dystrophy market barriers

Request for Sample PDF Report for Facioscapulohumeral Muscular Dystrophy Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Facioscapulohumeral Muscular Dystrophy Report Introduction
2. Facioscapulohumeral Muscular Dystrophy Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Overview
4. Facioscapulohumeral Muscular Dystrophy- Analytical Perspective In-depth Commercial Assessment
5. Facioscapulohumeral Muscular Dystrophy Pipeline Therapeutics
6. Facioscapulohumeral Muscular Dystrophy Late Stage Products (Phase II/III)
7. Facioscapulohumeral Muscular Dystrophy Mid Stage Products (Phase II)
8. Facioscapulohumeral Muscular Dystrophy Early Stage Products (Phase I)
9. Facioscapulohumeral Muscular Dystrophy Preclinical Stage Products
10. Facioscapulohumeral Muscular Dystrophy Therapeutics Assessment
11. Facioscapulohumeral Muscular Dystrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Facioscapulohumeral Muscular Dystrophy Key Companies
14. Facioscapulohumeral Muscular Dystrophy Key Products
15. Facioscapulohumeral Muscular Dystrophy Unmet Needs
16 . Facioscapulohumeral Muscular Dystrophy Market Drivers and Barriers
17. Facioscapulohumeral Muscular Dystrophy Future Perspectives and Conclusion
18. Facioscapulohumeral Muscular Dystrophy Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Facioscapulohumeral Muscular Dystrophy Market https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Facioscapulohumeral Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Facioscapulohumeral Muscular Dystrophy Epidemiology https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Facioscapulohumeral Muscular Dystrophy Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.